Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma
TP53 mutations and copy‑number loss are associated with poorer overall survival in newly diagnosed large B-cell lymphoma patients treated with standard immunochemotherapy.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
- Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
- Lymphoma Clinical Trials and Research
- Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial
- Englumafusp alfa plus glofitamab in B cell non‑Hodgkin lymphoma: a phase 1 trial